Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors

CS Shemesh, Y Wang, A An, H Ding, P Chan… - Cancer Chemotherapy …, 2024 - Springer
Purpose Tiragolumab is an immunoglobulin G1 monoclonal antibody targeting the immune
checkpoint T cell immunoreceptor with immunoglobulin and immunoreceptor ITIM domains …

Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells

D Piovesan, AE de Groot, S Cho, AE Anderson… - Cancer Research, 2024 - AACR
T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory
motif domains (TIGIT) is an inhibitory receptor on immune cells that outcompetes an …